Direct answer. A 12-person open-label Phase 2a study reported changes in painful lipoma volume and pain. In September 2026, Caliway announced a separate 19-person placebo-controlled Phase 2 study that met its Week 20 pain endpoint; the public announcement is a sponsor report, not a peer-reviewed paper.
Which Dercum studies are being discussed?
The NCT05387733 record identifies an open-label, randomized Phase 2a study in 12 adults with Dercum disease and painful lipomas. Two active-dose groups were compared; there was no placebo arm. The published report examines ultrasound-assessed lipoma volume and pain over a short follow-up. “Randomized” here describes assignment between active groups, not protection against expectations through a masked placebo comparison. That distinction matters for a subjective pain outcome.
The later NCT06303570 record names protocol CBL-0202DD. It lists 19 actual enrollees, a randomized placebo-controlled design and a Week 20 primary pain measure on a 0-to-10 Comparative Pain Scale. Caliway’s 21 September 2026 announcement reports the study’s final statistical analysis. These are two separate cohorts and designs. The older lipoma-volume result cannot be substituted for the newer pain comparison.
Study identifiers and designs
- NCT05387733: 12 adults, two active groups, open label.
- NCT06303570: 19 actual enrollees in the registry, placebo-controlled, Week 20 pain endpoint.
- The publication and the 2026 sponsor announcement have different evidentiary status.
What do the reported pain numbers mean?
For CBL-0202DD, the sponsor reports a mean Week 20 reduction of 3.1 points with CBL-514 and 1.9 points with placebo in the full analysis set, with p=0.005. It also reports Week 16 and Week 24 changes. A reduction means the recorded pain score was lower than baseline at the named visit; the placebo group’s improvement remains part of the result. The company calls the primary endpoint statistically significant. The registry defines the planned scale and time point, while the announcement supplies the analyzed result.
The Phase 2a paper describes lipoma dimensions as well as pain. Its figure notes show that baseline lipoma sizes varied and that missing data were imputed using last observation carried forward. Comparing its percentage volume change with a 0-to-10 pain-score change would mix different units and populations. The 2026 sponsor summary does not provide the same depth of methods, adverse-event tables and participant flow as a full peer-reviewed report; treat it as a dated update pending fuller publication.
Keep each result in its unit
- Pain: change in points on the stated scale, with treatment and placebo values.
- Volume: ultrasound measurement of selected lipomas, with baseline size and follow-up.
- A p value describes the reported comparison, not a personal probability of benefit.
What remains unproven for a reader?
Neither study establishes that every ordinary lipoma will respond or that pain relief will persist beyond the measured interval. Dercum disease is a specific painful-fat disorder; the enrolled adults met defined eligibility criteria. The Phase 2a publication itself notes its small sample, lack of a comparator and short follow-up. The placebo-controlled study improves the design for a pain question, but its sponsor announcement still needs the complete report for a detailed assessment of missing data, subgroup effects and harms.
Caliway describes a distinct CBL-514D development formulation for Dercum disease in its 2026 communications. A vial offered elsewhere under a similar name is not thereby linked to either study. The indication guide keeps Dercum disease, cellulite and abdominal-fat research separate. For study participation, consult the official registry and a clinician; for an evidence review, cite the NCT number, paper or announcement date, endpoint and analysis group in the same sentence as any figure.
Limits to carry forward
- Dercum lipomas are not all lipomas.
- Sponsor-reported findings and peer-reviewed results must be labelled separately.
- A clinical result does not identify a third-party research vial.
Reviewed 31 October 2026. This editorial review summarizes named public sources and does not offer treatment or identify any third-party vial as the developer’s clinical formulation.
Frequently asked questions
Was the 12-person Dercum study placebo-controlled?
No. NCT05387733 randomized participants between two active-dose groups and was open label.
What was the primary endpoint in CBL-0202DD?
The NCT06303570 registry specifies a Week 20 pain comparison using the 0-to-10 Comparative Pain Scale.
Where does the 3.1 versus 1.9 point figure come from?
It is Caliway’s 21 September 2026 announcement for the full analysis set at Week 20, not a number from the earlier 12-person paper.
Do these results prove a treatment for all lipomas?
No. The studies enrolled people with Dercum disease under specific criteria and measured defined outcomes over limited follow-up.